Breaking News


Comparative efficacy of therapies for moderate-severe psoriasis


A meta-analysis of published randomized trials (1966-2008) reporting 6-14-week treatment efficacy for moderate-severe psoriasis using the Psoriasis Area and Severity Index (PASI) was conducted. Nineteen studies were suitable for inclusion. The treatments that effected a  50% or greater reduction in the PASI included: psoralen and UVA (PUVA) and acitretin (97%); infliximab (84%); adalimumab 40 mg (77%); UVB (73%); etanercept 50 mg (66%); oral PUVA (61%); acitretin 50 mg (57%); etanercept 25 mg (55%); and methotrexate 12 mg (52%). Cyclosporin, alefacept and efalizumab had efficacy rates below 50% (Kankin, C. et al. 10th Int Congr Dermatol (May 20-24, Prague) 2009, Abst P345, 1252).

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list